Published in Br J Clin Pharmacol on September 01, 1999
Recommendations for the management of cough in adults. Thorax (2006) 2.41
Cough challenge in the assessment of cough reflex. Br J Clin Pharmacol (2001) 1.05
Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. Br J Clin Pharmacol (2003) 0.91
A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. Drug Metab Dispos (2013) 0.91
Assessment of antitussive efficacy of dextromethorphan in smoking related cough: objective vs. subjective measures. Br J Clin Pharmacol (2008) 0.88
Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole. Drug Metab Dispos (2011) 0.85
Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. Br J Clin Pharmacol (2001) 0.84
A randomized placebo controlled trial to evaluate the effects of butamirate and dextromethorphan on capsaicin induced cough in healthy volunteers. Br J Clin Pharmacol (2014) 0.81
Validation of the ERS standard citric acid cough challenge in healthy adult volunteers. Cough (2010) 0.78
Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort. Pharmacogenomics J (2015) 0.76
Pharmacogenetics informed decision making in adolescent psychiatric treatment: a clinical case report. Int J Mol Sci (2015) 0.75
Effect of a single dose of dextromethorphan on psychomotor performance and working memory capacity. Indian J Psychol Med (2012) 0.75
Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr (1977) 2.43
Evaluation of a new antitussive agent. N Engl J Med (1953) 1.29
The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther (1996) 1.24
Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol (1986) 1.23
Evaluation of antitussive agents in man. Pulm Pharmacol (1997) 1.21
Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit (1990) 1.08
Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis. Clin Pharmacol Ther (1989) 1.05
CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics (1993) 1.04
Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol (1994) 0.98
Dextromethorphan and codeine: comparison of plasma kinetics and antitussive effects. Eur J Respir Dis (1984) 0.98
Dextromethorphan and codeine: objective assessment of antitussive activity in patients with chronic cough. J Int Med Res (1983) 0.98
Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism. Br J Clin Pharmacol (1990) 0.97
The effect of inhaled and oral dextromethorphan on citric acid induced cough in man. Br J Clin Pharmacol (1995) 0.95
Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther (1992) 0.92
Inhalation cough challenge in the investigation of the cough reflex and antitussives. Pulm Pharmacol (1997) 0.92
A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Br J Clin Pharmacol (1990) 0.91
Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol (1998) 0.89
The urinary excretion of dextromethorphan and three metabolites in dogs and humans. Toxicol Appl Pharmacol (1980) 0.89
CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics (1997) 0.87
Quantitative comparison of cough-suppressing effects of romilar and other antitussives. J Lab Clin Med (1956) 0.87
Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharm Drug Dispos (1997) 0.87
Antitussive effect of dextromethorphan and dextromethorphan-salbutamol combination in healthy volunteers with artificially induced cough. Respiration (1987) 0.85
Dextrorphan and dextromethorphan: comparative antitussive effects on guinea pigs. Drugs Exp Clin Res (1994) 0.80
A comparative survey of the results of analyses of blood serum in clinical chemistry laboratories in the United Kingdom. J Clin Pathol (1973) 3.44
Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists. Br J Clin Pharmacol (1981) 3.07
Optimality in human motor performance: ideal control of rapid aimed movements. Psychol Rev (1988) 2.98
Oxidation phenotype--a major determinant of metoprolol metabolism and response. N Engl J Med (1982) 2.72
Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr (1977) 2.43
Amiodarone pharmacokinetics. Am Heart J (1983) 2.42
Exhaled breath condensate pH and exhaled nitric oxide in allergic asthma and in cystic fibrosis. Thorax (2005) 2.39
Breath carbon monoxide as an indication of smoking habit. Chest (2000) 2.38
Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol (1981) 2.38
T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology (2008) 2.38
Neuroimaging features of neurodegeneration with brain iron accumulation. AJNR Am J Neuroradiol (2011) 2.30
Urinary tract in schoolgirls with covert bacteriuria. Arch Dis Child (1975) 2.21
Pheromone binding to two rodent urinary proteins revealed by X-ray crystallography. Nature (1992) 2.20
Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma. Nature (1990) 2.20
Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility. Br J Clin Pharmacol (1981) 2.08
The online Cough Clinic: developing guideline-based diagnosis and advice. Eur Respir J (2009) 2.07
Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. Clin Infect Dis (1996) 1.98
Possible chemical contribution from chromic gut sutures produces disorders of pain sensation like those seen in man. Pain (1993) 1.93
An outbreak of Burkholderia (formerly Pseudomonas) cepacia respiratory tract colonization and infection associated with nebulized albuterol therapy. Ann Intern Med (1995) 1.88
Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol (1996) 1.86
Investigation and management of chronic cough using a probability-based algorithm. Eur Respir J (2005) 1.82
The role of steroids and their effects on phospholipase A2. An animal model of radiculopathy. Spine (Phila Pa 1976) (1998) 1.77
Molecular epidemiology of infections due to Enterobacter aerogenes: identification of hospital outbreak-associated strains by molecular techniques. Clin Infect Dis (1995) 1.76
Antitussive activity of iodo-resiniferatoxin in guinea pigs. Thorax (2004) 1.73
Binding of anilide-type local anesthetics in human plasma. I. Relationships between binding, physicochemical properties, and anesthetic activity. Anesthesiology (1970) 1.71
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol (1992) 1.71
Polymorphic hydroxylation of debrisoquine. Lancet (1977) 1.69
Plasma concentrations of local anaesthetics after interscalene brachial plexus block. Br J Anaesth (1977) 1.66
Gall-bladder sensitivity to cholecystokinin in patients with gall stones. Br Med J (1980) 1.64
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. Br J Clin Pharmacol (1985) 1.64
Cough hypersensitivity syndrome: a distinct clinical entity. Lung (2010) 1.61
An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) Eur Respir J (1997) 1.60
A six-year evaluation of methadone prescribing practices at a substance misuse treatment centre in the UK. J Clin Pharm Ther (2006) 1.58
Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing. Br J Clin Pharmacol (1982) 1.55
Targetting voltage-gated calcium channels in cardiovascular therapy. Lancet (2000) 1.52
Cough in the community: a cross sectional survey and the relationship to gastrointestinal symptoms. Thorax (2006) 1.52
Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. Br J Clin Pharmacol (1982) 1.52
Lack of effect of atenolol on antipyrine clearance. Br J Clin Pharmacol (1982) 1.51
99mTc dimercaptosuccinic acid (DMSA) scan as first investigation of urinary tract infection. Arch Dis Child (1988) 1.48
Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet (1979) 1.47
Stroke after coronary artery operation: incidence, correlates, outcome, and cost. Ann Thorac Surg (2000) 1.46
Atopic cough: little evidence to support a new clinical entity. Thorax (2003) 1.45
Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine. CPT Pharmacometrics Syst Pharmacol (2013) 1.44
Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics (1996) 1.41
Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J Pharmacol Exp Ther (2000) 1.41
Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies. Acta Psychiatr Scand (2010) 1.41
Ketamine: relief from chronic pain through actions at the NMDA receptor? Pain (1996) 1.41
Gerontokinetics--a reappraisal. Br J Clin Pharmacol (1992) 1.41
Inoprotection: the perioperative role of levosimendan. Anaesth Intensive Care (2007) 1.40
High-dose methylprednisolone sodium succinate as a single agent in relapsed childhood acute lymphoblastic leukaemia. Med Pediatr Oncol (1992) 1.39
Meperidine kinetics in man. Intravenous injection in surgical patients and volunteers. Clin Pharmacol Ther (1975) 1.39
Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol (1996) 1.39
Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol (1997) 1.37
Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther (1988) 1.37
Measurement of the renal clearance of drugs. Br J Clin Pharmacol (1981) 1.35
Patients' and carers' preferences in two models of care for acute exacerbations of COPD: results of a randomised controlled trial. Thorax (2002) 1.34
Nitric oxide mediates the thermal hyperalgesia produced in a model of neuropathic pain in the rat. Neuroscience (1992) 1.32
Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther (1986) 1.32
Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin Pharmacokinet (1993) 1.30
Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol (1986) 1.29
Cough threshold in patients with chronic obstructive pulmonary disease. Thorax (1999) 1.29
Lignocaine and indocyanine green kinetics in patients following myocardial infarction. Br J Clin Pharmacol (1980) 1.28
Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. Horm Metab Res (2001) 1.28
Taurine: biological update. Annu Rev Biochem (1986) 1.27
Why hypertensive patients vary in their response to oral debrisoquine. Br Med J (1977) 1.25
Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety (2000) 1.25
Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica (2006) 1.24
The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol (1994) 1.24
Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos (1997) 1.23
Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther (1983) 1.22
Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol (1999) 1.21
Intracolonic zymosan produces visceral hyperalgesia in the rat that is mediated by spinal NMDA and non-NMDA receptors. Brain Res (1996) 1.21
NADPH oxidase: a universal oxygen sensor? Free Radic Biol Med (2000) 1.18
Vascular amplifier properties in renovascular hypertension in conscious rabbits. Hindquarter responses to constrictor and dilator stimuli. Hypertension (1987) 1.17
Intra-articular morphine and/or bupivacaine in the management of pain after total knee arthroplasty. J Arthroplasty (1997) 1.17
The combining site of the dinitrophenyl-binding immunoglobulin A myeloma protein MOPC 315. Biochem J (1977) 1.17
Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther (1996) 1.16
The disposition of debrisoquine in hypertensive patients. Br J Clin Pharmacol (1978) 1.16
Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol (2001) 1.15
Genetic heterogeneity of I-cell disease is demonstrated by complementation of lysosomal enzyme processing mutants. Am J Med Genet (1982) 1.14
The antitussive effects of menthol, camphor and cineole in conscious guinea-pigs. Pulm Pharmacol (1994) 1.14
A comparative study of the effects of citric acid, capsaicin and resiniferatoxin on the cough challenge in guinea-pig and man. Pulm Pharmacol (1993) 1.13